Solidus Investment

Solidus Investment Co., Ltd, founded in June 2011 and based in Seoul, South Korea, is a venture capital firm that focuses on identifying and investing in companies with high growth potential. The firm primarily targets sectors such as bio/agriculture, marine products, green energy, and information technology. Through its investments, Solidus aims to support innovative businesses that contribute to advancements in these industries.

Jeong Hyun Kim

CEO

18 past transactions

Pharos iBio Co.

Series C in 2021
Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases.

Market Designers

Series B in 2019
Market Designers have been keeping an eye on the massive brick-and-mortar market, where online innovation is creating new opportunities. They are currently developing housing businesses such as running and cleaning. They are innovating market structure with innovative edutech technology and optimal methodology based on the characteristics of each market.

Orum Therapeutics

Series B in 2019
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibody therapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.

MOTIV Intelligence

Series B in 2018
MOTIV Intelligence is an AD-Tech company that automates the marketing process.

Orum Therapeutics

Series A in 2017
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibody therapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.

essys

Venture Round in 2015
essys is a Manufacturing and sales of automotive IT parts.

Vitrosys

Venture Round in 2014
Vitrosys is a biologics company. They intended to create a complete plant-based medicine from a single cell. They offer a research center for biotechnology, the industrialization of beneficial plant resources employing GMP and bioreactors for the manufacturing of functional foods that promote health, and a high-value clone seedling collection.

Techcross

Venture Round in 2014
Techcross is a Ballast Water Treatment Facility.

Purunagun Distribution

Venture Round in 2014
Purunagun Distribution is a Manufacture and distribution of ice cream with domestic agricultural products.

AnyGen

Venture Round in 2014
Anijen Co., Ltd. is the first bio-venture company in Gwangju and Jeonnam province. Since its establishment in 2000, it has developed peptide biomaterial process and developed quality management technology. They are making efforts to advance into the global market based on their competitiveness. In 2016, it was listed on the KOSDAQ market based on its proprietary peptide biomaterials and new drug development technology. They are supplying Peptide Medicinal Materials of high quality, which have been approved by GMP for the first time in Korea, at a reasonable price in the peptides drug materials market, which is dominated by a small number of companies worldwide. This stabilizes the supply price of peptide drug raw materials, And contribute to the promotion of public health.

Cheongwoo Food

Venture Round in 2014
Cheongwoo Food is a Comprehensive Confectionery.

Genomictree

Venture Round in 2014
Genomictree, Inc. Epigenomic Biomarker-Based Molecular Diagnostics Company.

Alteogen

Series A in 2013
Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics. Alteogen focus on the three cutting edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with complexity. Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting biobetter technology on its own, developed NexMab™ ADC Technology, an Antibody-Drug Conjugate technology, novel human hyaluronidase PH 20 based on Hybrozyme Technology and is jointly developing Antibody Biosimilars with overseas strategic alliance partners.

IDAL SYSTEM

Venture Round in 2013
IDAL SYSTEM is a Smart RPC Management System.

Novarex

Post in 2013
Novarex develops and produces health functional foods and raw materials in South Korea and internationally. Novarex offers lactic acid bacteria, eye health, diet, pregnant, children's, powdered general food, prostate health, omega-3, and vitamin and mineral products, as well as GNC and BLACKMORES products in the forms of tablet, hard capsule, and powder, gumi jelly, and stick jelly. The company was formerly known as Health Science Co., Ltd. and changed its name to Novarex Co., Ltd. in November 2011. Novarex Co., Ltd. was founded in 2008 and is headquartered in Cheongju, South Korea.

BioLeaders

Venture Round in 2012
BioLeaders is a health care group that provides total health care services. They provide medicines for cancer treatments. They also innovate a medicine for the 2b clinical stage; and non-clinical vaccine adjuvant and treatment for muscular dystrophy.

Kukdae F&B

Venture Round in 2012
Kookdae F & B is a franchise business.

Maniker F&G

Venture Round in 2012
Maniker F & G Co., Ltd. has been striving to provide customers with delicious and safe products based on advanced meat processing technology since 2004. We will be reborn as a global food company that provides health and convenience to customers with more advanced products through unlimited challenges and innovation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.